Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors
作者:Chen Chen、Xinying Yang、Hao Fang、Xuben Hou
DOI:10.1016/j.ejmech.2019.111563
日期:2019.11
Matrixmetalloproteinases (MMPs) play important roles in many diseases including cancer. With moderate metal-binding affinity, 8-hydroxyquinoline has gained much interest in current drug design and development. Specially, it has been reported that 8-hydroxyquinoline derivatives serve as MMP-2 inhibitors with micromolar IC50 values. In the current study, a series of 8-hydroxyquinoline derivatives were
of novel molecules were developed. All synthesized compounds were tested for their acetyl and butyryl cholinestrases (AChE and BChE) inhibitoryproperties. Enzyme inhibition and PAS binding studies identified compound 13b as a lead molecule with potent inhibitor property towards AChE/BChE (AChE IC50 = 0.96 ± 0.14 µM, BChE IC50 = 1.23 ± 0.23 µM) compared to earlier identified lead molecule EJMC-G (AChE
在我们之前的论文中,我们描述了基于阿魏酸 ( FA ) 模板的新型多功能胆碱酯酶 (ChE) 抑制剂系列,用于治疗 AD。本报告以校准的方式进一步扩展了该系列分子的构效关系 (SAR) 研究,以提高对 ChE 的抑制和抗氧化性能,从而鉴定出新型强效多功能分子。研究用苄基哌嗪取代苯基哌嗪环的效果,增加FA之间的接头长度和取代苯环,并在该分子模板上用色胺取代吲哚部分,开发了三个系列的新分子。测试了所有合成化合物的乙酰胆碱酯酶和丁酰胆碱酯酶(AChE 和 BChE)抑制特性。酶抑制和PAS结合研究鉴定的化合物13B,为先导分子朝向乙酰胆碱酯酶/ BChE的强效抑制剂属性胆碱酯酶(AChE的IC 50 = 0.96±0.14 μ男,IC的BChE 50 = 1.23±0.23 μ M)相比,先前确定先导分子EJMC- G(AChE IC 50 = 5.74 ± 0.13 μ M,BChE IC 50
2-[3-[2-[(2<i>S</i>)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: A Potent, Selective, and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV
peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidiabetic drugs. Most known DPP-IV inhibitors often resemble the dipeptide cleavage products, with a proline mimic at the P1 site. As off-target inhibitions of DPP8 and/or DPP9 have shown profound toxicities in the in vivo studies, it is important to develop selective DPP-IV inhibitors for clinical usage. To achieve this, a new class
[EN] PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS<br/>[FR] PYRIDOPYRIMIDINES EN TANT QU'INHIBITEURS DU RÉCEPTEUR H4 DE L'HISTAMINE
申请人:FAES FARMA SA
公开号:WO2020020939A1
公开(公告)日:2020-01-30
The invention relates to compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions comprising them and to their use in the treatment and/or prevention of diseases or disorders mediated by histamine H4 receptor.
Dioxygen Activation with Molybdenum Complexes Bearing Amide-Functionalized Iminophenolate Ligands
作者:Niklas Zwettler、Madeleine A. Ehweiner、Jörg A. Schachner、Antoine Dupé、Ferdinand Belaj、Nadia C. Mösch-Zanetti
DOI:10.3390/molecules24091814
日期:——
Two novel iminophenolate ligands with amidopropyl side chains (HL2 and HL3) on the imine functionality have been synthesized in order to prepare dioxidomolybdenum(VI) complexes of the general structure [MoO2L2] featuring pendant internal hydrogenbond donors. For reasons of comparison, a previously published complex featuring n-butyl side chains (L1) was included in the investigation. Three complexes